Reducing administrative costs in US health care: Assessing single payer and its alternatives.


Journal

Health services research
ISSN: 1475-6773
Titre abrégé: Health Serv Res
Pays: United States
ID NLM: 0053006

Informations de publication

Date de publication:
08 2021
Historique:
pubmed: 1 4 2021
medline: 15 12 2021
entrez: 31 3 2021
Statut: ppublish

Résumé

Excess administrative costs in the US health care system are routinely referenced as a justification for comprehensive reform. While there is agreement that these costs are too high, there is little understanding of what generates administrative costs and what policy options might mitigate them. Literature review and national utilization and expenditure data. We developed a simulation model of physician billing and insurance-related (BIR) costs to estimate how certain policy reforms would generate savings. Our model is based on structural elements of the payment process in the United States and considers each provider's number of health plan contracts, the number of features in each health plan, the clinical and nonclinical processes required to submit a bill for payment, and the compliance costs associated with medical billing. For several types of visits, we estimated fixed and variable costs of the billing process. We used the model to estimate the BIR costs at a national level under a variety of policy scenarios, including variations of a single payer "Medicare-for-All" model that extends fee-for-service Medicare to the entire population and policy efforts to reduce administrative costs in a multi-payer model. We conducted sensitivity analyses of a wide variety of model parameters. Our model estimates that national BIR costs are reduced between 33% and 53% in Medicare-for-All style single-payer models and between 27% and 63% in various multi-payer models. Under a wide range of assumptions and sensitivity analyses, standardizing contracts generates larger savings with less variance than savings from single-payer strategies. Although moving toward a single-payer system will reduce BIR costs, certain reforms to payer-provider contracts could generate at least as many administrative cost savings without radically reforming the entire health system. BIR costs can be meaningfully reduced without abandoning a multi-payer system.

Identifiants

pubmed: 33788283
doi: 10.1111/1475-6773.13649
pmc: PMC8313956
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

615-625

Informations de copyright

© 2021 Health Research and Educational Trust.

Références

Health Serv Res. 2021 Aug;56(4):615-625
pubmed: 33788283
Health Aff (Millwood). 2009 Jul-Aug;28(4):w544-54
pubmed: 19443478
Health Aff (Millwood). 2014 Sep;33(9):1586-94
pubmed: 25201663
Health Aff (Millwood). 2009 Jul-Aug;28(4):w533-43
pubmed: 19443477
Am Econ Rev. 2017 Feb;107(2):562-91
pubmed: 29553228
JAMA. 2019 Jun 25;321(24):2399-2400
pubmed: 31150046
Health Aff (Millwood). 2011 Aug;30(8):1443-50
pubmed: 21813866
JAMA. 2018 Feb 20;319(7):691-697
pubmed: 29466590
JAMA. 2019 Oct 15;322(15):1501-1509
pubmed: 31589283
Health Aff (Millwood). 2005 Nov-Dec;24(6):1629-39
pubmed: 16284038
N Engl J Med. 2003 Aug 21;349(8):768-75
pubmed: 12930930

Auteurs

David Scheinker (D)

Systems Utilization Research for Stanford Medicine, Stanford University, Stanford, California, USA.
Clinical Excellence Research Center, School of Medicine, Stanford University, Stanford, California, USA.

Barak D Richman (BD)

Clinical Excellence Research Center, School of Medicine, Stanford University, Stanford, California, USA.
Duke University School of Law, Durham, North Carolina, USA.

Arnold Milstein (A)

Clinical Excellence Research Center, School of Medicine, Stanford University, Stanford, California, USA.

Kevin A Schulman (KA)

Clinical Excellence Research Center, School of Medicine, Stanford University, Stanford, California, USA.
Graduate School of Business, Stanford University, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH